Peptide YY (PYY) Function: PYY is released postprandially from L-cells in the intestine and acts to reduce appetite
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
Semaglutide works by increasing insulin production, decreasing glucagon secretion, and slowing gastric emptying
The STEP (Semaglutide Treatment Effect in People with obesity) trials, published in The New England Journal of Medicine , redefined expectations for metabolic care
Stopping either therapy without making necessary lifestyle adjustments can lead to weight gain